| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9246 | 2011 |
| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 8220 | 2015 |
| Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 4313 | 2010 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3693 | 2017 |
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3300 | 2019 |
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ... The Lancet 368 (9544), 1329-1338, 2006 | 3239 | 2006 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2642 | 2018 |
| Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ... Nature 468 (7326), 973-977, 2010 | 2633 | 2010 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2610 | 2012 |
| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2446 | 2014 |
| Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ... CA: a cancer journal for clinicians 67 (6), 472-492, 2017 | 2342 | 2017 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2071 | 2010 |
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, ... Cancer cell 18 (6), 683-695, 2010 | 1497 | 2010 |
| Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 1218 | 2014 |
| RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 1211 | 2012 |
| Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ... The lancet oncology 17 (9), 1248-1260, 2016 | 1144 | 2016 |
| Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ... The Lancet Oncology 19 (5), 672-681, 2018 | 926 | 2018 |
| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616-622, 2013 | 906 | 2013 |
| Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ... Journal of clinical oncology 28 (27), 4142-4148, 2010 | 886 | 2010 |
| Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022 | 756 | 2022 |
Ross HannanProfessor Ross Hannan, Centenary Chair of Cancer Research, Deputy Dean of ResearchVerified email at anu.edu.au
